Archives: Agenda

The Next-Generation DCT Blueprint: AI-powered Network and Study Design Agility 下一代 DCT 蓝图：AI 驱动的网络洞察与试验设计动态适应性

  • Embedding agility into study decision models to intelligently support decentralized and hybrid trial models.
  • Creating connected DCT ecosystems to shorten study timelines and reduce overall operational burden.
  • Leveraging AI-driven insights to optimize end-to-end patient support and long-term adherence.
  • Intelligent Medication Management & Safety Monitoring with smart pillboxes to enable closed-loop medication adherence and safety surveillance.
  • 将动态适应嵌入研究决策模型，智能支持去中心化和混合型试验模式。
  • 打造互联的 DCT 生态系统，缩短研究周期并降低整体运营负担。
  • 利用 AI 驱动洞察，优化端到端患者支持和长期依从性。
  • 通过智能药盒实现智能用药管理与安全监测，形成闭环用药依从性和安全监测。

OPENING KEYNOTE: China’s Biopharma Leap: From Fast-Follower to Global Innovator 开幕主题演讲：中国生物医药的跃升：从快速跟随到引领创新

China stands at an inflection point in global biopharma innovation. Having mastered the art of rapid development and commercialization as a fast-follower, the industry is now making a decisive strategic pivot towards becoming a true globald innovator. The rise of China-led international multi-center trials (MRCTs) and landmark global partnerships underscores a new reality: China is no longer just a vast market or a development executor, but a primary source of scientific insight and therapeutic value.

中国正处于全球生物医药创新的关键转折点。随着中国临床的蓬勃发展，现在已经逐渐引领全球创新。由中国主导的多中心临床试验（MRCT）以及具有里程碑意义的全球交易，正在展示着中国在临床试验中的角色转变——从全球申办方的执行中心，转变为科学前沿与医药创新的重要源头

  • From “Fast Follower” to Autonomous Innovation
  • Leveraging China’s Capabilities for Worldwide Development
  • From Local Assurance to Global Collaboration
  • Aligning Standards and Achieving Mutual Recognition
  • Building an Open, Collaborative Global Network
  • 从“快速跟随”到自主创新
  • 借助中国能力推动全球开发
  • 从本土保障到全球协作
  • 标准统一与互认
  • 建立开放、协作的全球网络

The Next-Generation DCT Blueprint: AI-powered Network and Study Design Agility 下一代 DCT 蓝图：AI 驱动的网络洞察与试验设计动态适应性

  • Embedding agility into study decision models to intelligently support decentralized and hybrid trial models.
  • Creating connected DCT ecosystems to shorten study timelines and reduce overall operational burden.
  • Leveraging AI-driven insights to optimize end-to-end patient support and long-term adherence.
  • Intelligent Medication Management & Safety Monitoring with smart pillboxes to enable closed-loop medication adherence and safety surveillance.

 

  • 将动态适应嵌入研究决策模型，智能支持去中心化和混合型试验模式。
  • 打造互联的 DCT 生态系统，缩短研究周期并降低整体运营负担。
  • 利用 AI 驱动洞察，优化端到端患者支持和长期依从性。
  • 通过智能药盒实现智能用药管理与安全监测，形成闭环用药依从性和安全监测。

How biotech companies can build operational excellence into trials from the outset 打造卓越的临床方案设计

  • Designing protocols with site and patient feasibility in mind to reduce complexity and accelerate recruitment.
  • Embedding operational planning early to improve timelines, budget predictability, and study execution.
  • Leveraging digital technologies, data, and AI to streamline trial management and reduce administrative burden.
  • Building collaborative partnerships with sites, CROs, and technology providers to drive efficient, high-quality trial delivery

 

  • 在方案设计阶段纳入中心和患者可行性考量，降低复杂度并加速招募。
  • 尽早嵌入运营规划，以改善时间线、预算可预测性和研究执行。
  • 利用数字技术、数据和 AI 简化试验管理并减少行政负担。
  • 与中心、CRO 和技术供应商建立协作伙伴关系，推动高效、高质量的试验交付。